Belief BioMed (“BBM”) and Grand Life Sciences Group Co., Ltd. (“Grand Life Sciences”) have entered into an exclusive partnership agreement. As part of the deal, Belief BioMed will provide Grand Life Sciences with commercialization rights for its investigational therapy, BBM-H803, across Mainland China, Hong Kong, Macau, and Taiwan.

This partnership reflects both companies’ commitment to combining their expertise and resources to speed up the product’s path to market, expand access to innovative treatments for patients with hemophilia A, and support the advancement of gene therapy. The agreement was formalized by Xiao Xiao, Co-founder, Chairman, and Chief Science Officer of Belief BioMed, and Zenghui Feng, Chairman of Grand Life Sciences.

Dr. Xiao Xiao stated that Belief BioMed is dedicated to advancing gene therapy, with a pipeline addressing both rare and common diseases to meet significant unmet medical needs. He highlighted the company’s milestone in 2025 with the launch of China’s first gene therapy for hemophilia B, BBM-H901, which introduced a new treatment option for patients. Looking ahead to hemophilia A, he expressed enthusiasm for the collaboration, noting that Belief BioMed’s clinical development strengths, combined with Grand Life Sciences’ commercialization expertise, will help accelerate bringing new gene therapies to patients in China.

Zenghui Feng emphasized that the partnership marks an important strategic step in strengthening Grand Life Sciences’ innovative portfolio. By leveraging the blood product resources of its subsidiary, Grand Shuyang, along with its deep experience in hematology, the company aims to work closely with Belief BioMed to advance hemophilia A treatment. He added that integrating advanced research capabilities with established commercialization infrastructure will help improve patient access more quickly, with the ultimate goal of reducing the burden of frequent treatments and minimizing the risks associated with bleeding episodes for patients.

Merck, known as MSD outside of the United States and Canada, was named one of America's Most JUST Companies for the sixth year in a row, marking the company's dedication to its employees, customers, communities, the environment, and shareholders. Merck was ranked No. 26 overall and No. 1 in the pharmaceuticals and biotech industry for the third year in a row, as well as the top company in the industry for communities and customers.

“We are honored to be recognized as America’s Most JUST Company in the pharmaceutical and biotech industry for the third year in a row. This recognition demonstrates our company’s longstanding commitment to operating responsibly on behalf of society, shareholders and all our stakeholders to enable a safe, sustainable and healthy future for patients and communities around the world,” said Robert M. Davis, chairman and chief executive officer, Merck.

JUST Capital collects and analyses corporate data to evaluate the 1,000 largest public U.S. companies across 20 Issues identified through extensive, ongoing public opinion research on Americans' attitudes toward responsible corporate behaviour for the annual Rankings. Since 2015, JUST Capital has engaged over 160,000 participants on a fully representative basis.
If you would like to learn more about Merck’s commitment to corporate responsibility click here.